Ideaya gains on positive mid-stage cancer drug data

Mensch und Maschine Software SE

12/09/2022 14:17

** Cancer drug developer Ideaya Biosciences Inc's shares
 IDYA.O  rise 8.1% to $10 premarket
    ** Co reports promising data from mid-stage trial testing
its combination therapy in metastatic uveal melanoma (MUM)
patients  urn:newsml:reuters.com:*:nPn2mt4jka
    ** Says partial remission observed in 4 of 8 patients given
the drug as a first-line of therapy
    ** MUM is a cancer of the uveal tract of the eye 
    ** Trial was testing a combination of the drugs darovasertib
and crizotinib
    ** IDYA targeting a potential registration-enabling trial in
Q1 
    ** Up to Friday's close, stock down 60.9% YTD 

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))